TW201713665A - 適用於治療與ntrk相關之病症的化合物及組合物 - Google Patents

適用於治療與ntrk相關之病症的化合物及組合物 Download PDF

Info

Publication number
TW201713665A
TW201713665A TW105127561A TW105127561A TW201713665A TW 201713665 A TW201713665 A TW 201713665A TW 105127561 A TW105127561 A TW 105127561A TW 105127561 A TW105127561 A TW 105127561A TW 201713665 A TW201713665 A TW 201713665A
Authority
TW
Taiwan
Prior art keywords
group
etoac
ring
mmol
mixture
Prior art date
Application number
TW105127561A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文 馬克 溫洛斯基
娜塔莎 布魯傑孟
昌德拉塞卡 曼德拉
尼爾 比富爾科
Original Assignee
藍印藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 藍印藥品公司 filed Critical 藍印藥品公司
Publication of TW201713665A publication Critical patent/TW201713665A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW105127561A 2015-08-26 2016-08-26 適用於治療與ntrk相關之病症的化合物及組合物 TW201713665A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562210264P 2015-08-26 2015-08-26

Publications (1)

Publication Number Publication Date
TW201713665A true TW201713665A (zh) 2017-04-16

Family

ID=56896780

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105127561A TW201713665A (zh) 2015-08-26 2016-08-26 適用於治療與ntrk相關之病症的化合物及組合物

Country Status (17)

Country Link
US (2) US10017512B2 (enExample)
EP (1) EP3341374A1 (enExample)
JP (1) JP6877407B2 (enExample)
KR (1) KR20180043810A (enExample)
CN (1) CN108137607B (enExample)
AR (1) AR105836A1 (enExample)
AU (1) AU2016311426B2 (enExample)
BR (1) BR112018003588A2 (enExample)
CA (1) CA2995997A1 (enExample)
HK (1) HK1255330A1 (enExample)
IL (1) IL257702A (enExample)
MX (1) MX2018002407A (enExample)
PH (1) PH12018500397A1 (enExample)
RU (1) RU2744974C2 (enExample)
TW (1) TW201713665A (enExample)
WO (1) WO2017035354A1 (enExample)
ZA (1) ZA201801881B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015000653A2 (pt) 2012-07-11 2019-11-05 Blueprint Medicines Corp compostos inibidores do receptor de fator de crescimento de fibroblasto, sua composição farmacêutica e seus usos
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
PL3409674T3 (pl) 2013-10-17 2022-09-26 Blueprint Medicines Corporation Sposób wytwarzania kompozycji użytecznych do leczenia zaburzeń związanych z KIT
PH12016500739B1 (en) 2013-10-25 2022-04-29 Blueprint Medicines Corp Inhibitors of the fibrolast growth factor receptor
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
MX2018001032A (es) 2015-07-24 2018-11-09 Blueprint Medicines Corp Compuestos utiles para el tratamiento de trastornos relacionados con kit y pdgfr.
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
EP3371171B1 (en) 2015-11-02 2023-10-25 Blueprint Medicines Corporation Inhibitors of ret
CN108431008A (zh) 2015-11-19 2018-08-21 蓝图药品公司 可用于治疗与ntrk相关的病症的化合物和组合物
UY37155A (es) 2016-03-17 2017-10-31 Blueprint Medicines Corp Inhibidores de ret
PL3442977T3 (pl) 2016-04-15 2024-03-04 Blueprint Medicines Corporation Inhibitory kinazy podobnej do receptora aktywiny
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
CN113735881A (zh) 2017-08-23 2021-12-03 正大天晴药业集团股份有限公司 含有氨基吡唑并嘧啶的大环化合物及其药物组合物和用途
EP3697786B1 (en) 2017-10-18 2022-08-31 Blueprint Medicines Corporation Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
WO2019152982A1 (en) * 2018-02-05 2019-08-08 Shenzhen Ionova Life Science Co., Ltd. Heterobicyclic compounds as ep4 antagonists
BR112020019399A2 (pt) * 2018-03-28 2021-01-05 Fochon Pharmaceuticals, Ltd. Compostos macrocíclicos como inibidores de trk quinases
WO2019195471A1 (en) 2018-04-03 2019-10-10 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
SG11202109035QA (en) * 2019-02-27 2021-09-29 Ferro Therapeutics Inc Compounds with ferroptosis inducing activity and methods of their use
EP4302761A3 (en) 2019-04-12 2024-03-27 Blueprint Medicines Corporation Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
IL320038A (en) * 2019-11-25 2025-06-01 Alkermes Inc Substituted macrocyclic compounds compositions comprising same and uses thereof
CA3183728A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
CN113408945B (zh) * 2021-07-15 2023-03-24 广西中烟工业有限责任公司 一种烤烟纯度的检测方法、装置、电子设备及存储介质

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69732780T2 (de) * 1996-10-02 2006-04-06 Novartis Ag Pyrimiderivate und verfahren zu ihrer herstellung
TWI344468B (en) 2002-09-04 2011-07-01 Schering Corp Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7329662B2 (en) 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
MY143225A (en) * 2004-04-02 2011-03-31 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
JP5213229B2 (ja) * 2004-04-23 2013-06-19 エグゼリクシス, インコーポレイテッド キナーゼ調節因子および使用方法
WO2009032703A1 (en) * 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
LT3106463T (lt) 2008-10-22 2018-06-25 Array Biopharma, Inc. Pakeistieji pirazolo[1,5-]pirimidino junginiai kaip trk kinazės slopikliai
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CN102471342A (zh) * 2010-05-05 2012-05-23 沃泰克斯药物股份有限公司 用作PKC-θ抑制剂的4取代的吡唑并吡啶类
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
CN102241678B (zh) 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
BR112015000653A2 (pt) 2012-07-11 2019-11-05 Blueprint Medicines Corp compostos inibidores do receptor de fator de crescimento de fibroblasto, sua composição farmacêutica e seus usos
EP2890815B1 (en) * 2012-08-31 2019-03-20 The Regents of the University of Colorado Methods for diagnosis and treatment of cancer
SG11201502527UA (en) 2012-10-05 2015-04-29 Rigel Pharmaceuticals Inc Gdf-8 inhibitors
EP2914621B1 (en) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
JP2016506944A (ja) * 2013-02-01 2016-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピラゾロピリミジニルアミノ−インダゾール
CN103965199B (zh) 2013-02-02 2017-07-07 广东东阳光药业有限公司 一种芳杂环化合物、包含它的药物组合物及其用途
MX2015010700A (es) 2013-02-21 2017-01-23 Calitor Sciences Llc Compuestos heteroaromaticos como moduladores de la p13 cinasa.
CN105980386B (zh) 2013-03-13 2021-08-13 基因泰克公司 吡唑并化合物及其用途
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
GB2515785A (en) * 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
PL3409674T3 (pl) 2013-10-17 2022-09-26 Blueprint Medicines Corporation Sposób wytwarzania kompozycji użytecznych do leczenia zaburzeń związanych z KIT
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
PH12016500739B1 (en) 2013-10-25 2022-04-29 Blueprint Medicines Corp Inhibitors of the fibrolast growth factor receptor
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
EP3129367B1 (en) 2014-04-08 2019-09-04 Rigel Pharmaceuticals, Inc. 2,3-disubstituted pyridine compounds as tgf-beta inhibitors
WO2016022569A1 (en) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
HUE067779T2 (hu) 2014-12-15 2024-11-28 Cmg Pharmaceutical Co Ltd Kondenzált gyûrûs heteroaril vegyületek és azok felhasználása TRK inhibitorokként
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
WO2016133838A1 (en) 2015-02-20 2016-08-25 Rigel Pharmaceuticals, Inc. Gdf-8 inhibitors
MX2018001032A (es) 2015-07-24 2018-11-09 Blueprint Medicines Corp Compuestos utiles para el tratamiento de trastornos relacionados con kit y pdgfr.
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
EP3371171B1 (en) 2015-11-02 2023-10-25 Blueprint Medicines Corporation Inhibitors of ret
CN108431008A (zh) 2015-11-19 2018-08-21 蓝图药品公司 可用于治疗与ntrk相关的病症的化合物和组合物
UY37155A (es) 2016-03-17 2017-10-31 Blueprint Medicines Corp Inhibidores de ret
PL3442977T3 (pl) 2016-04-15 2024-03-04 Blueprint Medicines Corporation Inhibitory kinazy podobnej do receptora aktywiny
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
CN107844168B (zh) 2017-11-23 2020-12-01 英业达科技有限公司 主板组件及其卡扣装置

Also Published As

Publication number Publication date
RU2744974C2 (ru) 2021-03-17
AU2016311426B2 (en) 2021-05-20
IL257702A (en) 2018-04-30
ZA201801881B (en) 2019-05-29
US20190169194A1 (en) 2019-06-06
PH12018500397A1 (en) 2018-08-29
RU2018110379A3 (enExample) 2019-12-26
US11046697B2 (en) 2021-06-29
CN108137607A (zh) 2018-06-08
WO2017035354A1 (en) 2017-03-02
BR112018003588A2 (pt) 2018-09-25
JP6877407B2 (ja) 2021-05-26
RU2018110379A (ru) 2019-09-27
KR20180043810A (ko) 2018-04-30
MX2018002407A (es) 2018-11-29
JP2018528200A (ja) 2018-09-27
CN108137607B (zh) 2021-04-06
EP3341374A1 (en) 2018-07-04
CA2995997A1 (en) 2017-03-02
US20170066773A1 (en) 2017-03-09
AU2016311426A1 (en) 2018-04-05
AR105836A1 (es) 2017-11-15
US10017512B2 (en) 2018-07-10
HK1255330A1 (zh) 2019-08-16

Similar Documents

Publication Publication Date Title
CN108137607B (zh) 适用于治疗与ntrk相关的病症的化合物和组合物
TWI871397B (zh) Kras突變蛋白抑制劑
TWI733713B (zh) 用於治療神經促進性酪氨酸受體激酶相關之異常的化合物與組成物
WO2023061294A1 (zh) 含氮杂环类衍生物调节剂、其制备方法及应用
JP2022525749A (ja) Jakキナーゼ阻害剤及びその調製方法、並びにその医薬分野での使用
CN114072407A (zh) 靶向prmt5的化合物
CN111918868A (zh) 作为蛋白激酶调节剂的二芳基大环化合物
TW202430162A (zh) 具有抗kras突變腫瘤活性的化合物
TW202346297A (zh) 具有抗kras突變腫瘤活性的化合物
CN114685502A (zh) 作为kras-g12c抑制剂的螺环类化合物
WO2019157879A1 (zh) 作为trk抑制剂的杂环化合物
EP3632903A1 (en) Compound used as autophagy regulator, and preparation method therefor and uses thereof
CN117157297A (zh) Prmt5抑制剂
CN106661032A (zh) 治疗或预防糖尿病、肥胖症和炎性肠病的1,3‑取代的2‑氨基吲哚衍生物及类似物
CN115867346A (zh) 激酶抑制剂
CN114805311A (zh) 螺环茚
WO2023237085A1 (zh) Hpk1抑制剂及其在医药上的应用
CN116354932A (zh) 嘧啶衍生物及其制备方法和用途
HK40065459A (en) Kras mutant protein inhibitors
HK40003732B (zh) 激活素受体样激酶抑制剂